These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 39168404)

  • 1. Designed dualsteric modulators: A novel route for drug discovery.
    Li N; Zheng G; Fu L; Liu N; Chen T; Lu S
    Drug Discov Today; 2024 Oct; 29(10):104141. PubMed ID: 39168404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing drugs and chemical probes with the dualsteric approach.
    Zha J; He J; Wu C; Zhang M; Liu X; Zhang J
    Chem Soc Rev; 2023 Dec; 52(24):8651-8677. PubMed ID: 37990599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors.
    Mohr K; Schmitz J; Schrage R; Tränkle C; Holzgrabe U
    Angew Chem Int Ed Engl; 2013 Jan; 52(2):508-16. PubMed ID: 23225228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational design of dualsteric GPCR ligands: quests and promise.
    Mohr K; Tränkle C; Kostenis E; Barocelli E; De Amici M; Holzgrabe U
    Br J Pharmacol; 2010 Mar; 159(5):997-1008. PubMed ID: 20136835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric Modulator Discovery: From Serendipity to Structure-Based Design.
    Lu S; He X; Ni D; Zhang J
    J Med Chem; 2019 Jul; 62(14):6405-6421. PubMed ID: 30817889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research progress of indole-fused derivatives as allosteric modulators: Opportunities for drug development.
    Luo ML; Zhao Q; He XH; Xie X; Zhu HP; You FM; Peng C; Zhan G; Huang W
    Biomed Pharmacother; 2023 Jun; 162():114574. PubMed ID: 36996677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.
    Gado F; Ferrisi R; Polini B; Mohamed KA; Ricardi C; Lucarini E; Carpi S; Domenichini F; Stevenson LA; Rapposelli S; Saccomanni G; Nieri P; Ortore G; Pertwee RG; Ghelardini C; Di Cesare Mannelli L; Chiellini G; Laprairie RB; Manera C
    J Med Chem; 2022 Jul; 65(14):9918-9938. PubMed ID: 35849804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of receptor allosterism and its implication for drug discovery.
    Zhang R; Kavana M
    Expert Opin Drug Discov; 2015 Jul; 10(7):763-80. PubMed ID: 25927503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.
    Reinecke BA; Wang H; Zhang Y
    Curr Top Med Chem; 2019; 19(26):2378-2392. PubMed ID: 31833462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing allostery: a novel approach to drug discovery.
    Lu S; Li S; Zhang J
    Med Res Rev; 2014 Nov; 34(6):1242-85. PubMed ID: 24827416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?
    Carli M; Kolachalam S; Aringhieri S; Rossi M; Giovannini L; Maggio R; Scarselli M
    Curr Neuropharmacol; 2018 Jan; 16(2):222-230. PubMed ID: 28521704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for the identification of allosteric modulators of G-protein-coupled receptors.
    Burford NT; Watson J; Bertekap R; Alt A
    Biochem Pharmacol; 2011 Mar; 81(6):691-702. PubMed ID: 21184747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors.
    Feng Z; Hu G; Ma S; Xie XQ
    AAPS J; 2015 Sep; 17(5):1080-95. PubMed ID: 25940084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric modulation of GPCRs: From structural insights to in silico drug discovery.
    Persechino M; Hedderich JB; Kolb P; Hilger D
    Pharmacol Ther; 2022 Sep; 237():108242. PubMed ID: 35863587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are the Apo Proteins Suitable for the Rational Discovery of Allosteric Drugs?
    An X; Lu S; Song K; Shen Q; Huang M; Yao X; Liu H; Zhang J
    J Chem Inf Model; 2019 Jan; 59(1):597-604. PubMed ID: 30525607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanobody-Mediated Dualsteric Engagement of the Angiotensin Receptor Broadens Biased Ligand Pharmacology.
    Braga Emidio N; Small BM; Keller AR; Cheloha RW; Wingler LM
    Mol Pharmacol; 2024 Feb; 105(3):260-271. PubMed ID: 38164609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric Methods and Their Applications: Facilitating the Discovery of Allosteric Drugs and the Investigation of Allosteric Mechanisms.
    Lu S; Shen Q; Zhang J
    Acc Chem Res; 2019 Feb; 52(2):492-500. PubMed ID: 30688063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.
    Lu S; Zhang J
    J Med Chem; 2019 Jan; 62(1):24-45. PubMed ID: 29457894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric modulators of G-protein-coupled receptors.
    May LT; Christopoulos A
    Curr Opin Pharmacol; 2003 Oct; 3(5):551-6. PubMed ID: 14559102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of allosteric modulators of GPCRs for treatment of CNS disorders.
    Nickols HH; Conn PJ
    Neurobiol Dis; 2014 Jan; 61():55-71. PubMed ID: 24076101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.